The role of 18F-FDG PET/CT in the management of testicular cancers

Gary J. Cook; Aslam Sohaib; Robert A. Huddart; David P. Dearnaley; Alan Horwich; Sue Chua

doi:10.1097/MNM.0000000000000303

The role of ¹⁸F-FDG PET/CT in the management of testicular cancers

Gary J. Cook^*, Aslam Sohaib, Robert A. Huddart, David P. Dearnaley, Alan Horwich, Sue Chua

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

Objectives: The aim of this study was to determine the utility of fluorine-18 fluorodeoxyglucose PET/computed tomography (¹⁸F-FDG PET/CT) in managing testicular cancer.

Patients and methods: Sixty-two patients (29 seminoma, 28 nonseminoma and five mixed) underwent 75 ¹⁸F-FDG PET/CT scans (16 scans for primary staging, 44 for residual masses and 15 for rising tumour markers). Follow-up histology, clinical scans and tumour marker results were included for retrospective analysis.

Results (i) Primary staging: eight of 11 patients with equivocal CT scans had true-negative ¹⁸F-FDG PET/CT scans. Five high-risk patients with normal stage 1 CT scans had negative¹⁸F-FDG PET/CT scans, but two subsequently relapsed. (ii) Residual masses: of the 20 scans interpreted as showing viable disease, five were false positive. Nineteen scans were negative (18 true negative and one false negative). (iii) Rising tumour markers: of the 15 scans, two were false negative and 13 were true positive.

Conclusion: ¹⁸F-FDG PET/CT is helpful when primary staging CT scans are equivocal but insufficiently sensitive to predict relapse in high-risk patients with normal CT scans. With residual masses, a negative scan is rarely associated with relapse. ¹⁸F-FDG PET/CT is helpful in defining recurrent disease in the majority of patients with rising tumour markers and negative CT scans.

Original language	English
Pages (from-to)	702-708
Number of pages	7
Journal	Nuclear Medicine Communications
Volume	36
Issue number	7
DOIs	https://doi.org/10.1097/MNM.0000000000000303
Publication status	Published - 1 Jul 2015

Keywords

18F-fluorodeoxyglucose PET/CT
residual mass
staging
testicular cancer
tumour markers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/MNM.0000000000000303

Cite this

@article{09e340f5c99a42b4b5e446a9f2211fad,

title = "The role of 18F-FDG PET/CT in the management of testicular cancers",

abstract = "Objectives: The aim of this study was to determine the utility of fluorine-18 fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) in managing testicular cancer. Patients and methods: Sixty-two patients (29 seminoma, 28 nonseminoma and five mixed) underwent 75 18F-FDG PET/CT scans (16 scans for primary staging, 44 for residual masses and 15 for rising tumour markers). Follow-up histology, clinical scans and tumour marker results were included for retrospective analysis.Results (i) Primary staging: eight of 11 patients with equivocal CT scans had true-negative 18F-FDG PET/CT scans. Five high-risk patients with normal stage 1 CT scans had negative18F-FDG PET/CT scans, but two subsequently relapsed. (ii) Residual masses: of the 20 scans interpreted as showing viable disease, five were false positive. Nineteen scans were negative (18 true negative and one false negative). (iii) Rising tumour markers: of the 15 scans, two were false negative and 13 were true positive. Conclusion: 18F-FDG PET/CT is helpful when primary staging CT scans are equivocal but insufficiently sensitive to predict relapse in high-risk patients with normal CT scans. With residual masses, a negative scan is rarely associated with relapse. 18F-FDG PET/CT is helpful in defining recurrent disease in the majority of patients with rising tumour markers and negative CT scans.",

keywords = "18F-fluorodeoxyglucose PET/CT, residual mass, staging, testicular cancer, tumour markers",

author = "Cook, {Gary J.} and Aslam Sohaib and Huddart, {Robert A.} and Dearnaley, {David P.} and Alan Horwich and Sue Chua",

year = "2015",

month = jul,

day = "1",

doi = "10.1097/MNM.0000000000000303",

language = "English",

volume = "36",

pages = "702--708",

journal = "Nuclear Medicine Communications",

issn = "0143-3636",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - The role of 18F-FDG PET/CT in the management of testicular cancers

AU - Cook, Gary J.

AU - Sohaib, Aslam

AU - Huddart, Robert A.

AU - Dearnaley, David P.

AU - Horwich, Alan

AU - Chua, Sue

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Objectives: The aim of this study was to determine the utility of fluorine-18 fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) in managing testicular cancer. Patients and methods: Sixty-two patients (29 seminoma, 28 nonseminoma and five mixed) underwent 75 18F-FDG PET/CT scans (16 scans for primary staging, 44 for residual masses and 15 for rising tumour markers). Follow-up histology, clinical scans and tumour marker results were included for retrospective analysis.Results (i) Primary staging: eight of 11 patients with equivocal CT scans had true-negative 18F-FDG PET/CT scans. Five high-risk patients with normal stage 1 CT scans had negative18F-FDG PET/CT scans, but two subsequently relapsed. (ii) Residual masses: of the 20 scans interpreted as showing viable disease, five were false positive. Nineteen scans were negative (18 true negative and one false negative). (iii) Rising tumour markers: of the 15 scans, two were false negative and 13 were true positive. Conclusion: 18F-FDG PET/CT is helpful when primary staging CT scans are equivocal but insufficiently sensitive to predict relapse in high-risk patients with normal CT scans. With residual masses, a negative scan is rarely associated with relapse. 18F-FDG PET/CT is helpful in defining recurrent disease in the majority of patients with rising tumour markers and negative CT scans.

AB - Objectives: The aim of this study was to determine the utility of fluorine-18 fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) in managing testicular cancer. Patients and methods: Sixty-two patients (29 seminoma, 28 nonseminoma and five mixed) underwent 75 18F-FDG PET/CT scans (16 scans for primary staging, 44 for residual masses and 15 for rising tumour markers). Follow-up histology, clinical scans and tumour marker results were included for retrospective analysis.Results (i) Primary staging: eight of 11 patients with equivocal CT scans had true-negative 18F-FDG PET/CT scans. Five high-risk patients with normal stage 1 CT scans had negative18F-FDG PET/CT scans, but two subsequently relapsed. (ii) Residual masses: of the 20 scans interpreted as showing viable disease, five were false positive. Nineteen scans were negative (18 true negative and one false negative). (iii) Rising tumour markers: of the 15 scans, two were false negative and 13 were true positive. Conclusion: 18F-FDG PET/CT is helpful when primary staging CT scans are equivocal but insufficiently sensitive to predict relapse in high-risk patients with normal CT scans. With residual masses, a negative scan is rarely associated with relapse. 18F-FDG PET/CT is helpful in defining recurrent disease in the majority of patients with rising tumour markers and negative CT scans.

KW - 18F-fluorodeoxyglucose PET/CT

KW - residual mass

KW - staging

KW - testicular cancer

KW - tumour markers

UR - http://www.scopus.com/inward/record.url?scp=84931063352&partnerID=8YFLogxK

U2 - 10.1097/MNM.0000000000000303

DO - 10.1097/MNM.0000000000000303

M3 - Article

AN - SCOPUS:84931063352

SN - 0143-3636

VL - 36

SP - 702

EP - 708

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

IS - 7

ER -